Renal function in African women receiving tenofovir disoproxil fumarate as pre‐exposure prophylaxis for HIV during pregnancy and postpartum: A postpartum safety analysis in the CAP016 randomized control trial Authors: Gaysheen Kistan, Tonya Esterhuizen, Megeshinee Naidoo, Alicia C. Desmond, Motshedisi Sebitloane, Dhayendre Moodley Published: 2026 ABSTRACT AbstractBackgroundThe effect of tenofovir disoproxil fumarate (TDF) when used as pre‐exposure prophylaxis (PrEP) on renal function in pregnant and postpartum women is understudied. An open‐label clinical trial (CAP016 study) was designed to examine the safety of TDF‐PrEP use during pregnancy and breastfeeding.MethodsWomen were randomized (1:1) to either initiate PrEP at enrolment in pregnancy (Immediate PrEP‐IP) or initiate PrEP (Deferred PrEP‐DP) at the time of breastfeeding cessation. We compared changes in creatinine clearance and frequency of adverse renal events in women randomized to initiate TDF‐PrEP in pregnancy versus women randomized to defer initiation of TDF‐PrEP to the time of breastfeeding cessation. Participants were recruited between 28 September 2017 and 3 December 2019. Serum creatinine was measured at baseline during pregnancy and at 6, 26, 54 and 74 weeks postpartum. Creatinine clearance (CrCl) (mL/min) was calculated using the Cockroft–Gault equation. CrCl ≥90 mL/min was considered normal, CrCl 60–90 mL/min (moderate) and CrCl <60 mL/min (abnormal). We used mixed‐effects linear regression models to test for differences in the change in CrCl between the IP and DP arms. The frequency of adverse renal events between the randomization arms was examined using χ2/Fisher's exact tests. The CAP016 parent study was registered on ClinicalTrials.gov under NCT03227731.ResultsMean difference in CrCl change from 6 to 74 weeks between IP and DP arms was −0.67% (p = 0.809). There was no correlation between randomization arm and change in CrCl over time (β‐2.08; p = 0.094). There were 16 (4%) moderate/Grade 2 CrCl abnormalities during the postpartum period, which were comparable between randomization arms. BMI of <18.5 kg/m2 was significantly associated with a moderate renal adverse event (OR 71.8; 95% CI 17.0–302.8) (p < 0.0001).ConclusionTenofovir disoproxil fumarate, when given in combination with emtricitabine as pre‐exposure prophylaxis during pregnancy and lactation, appears not to have an effect on creatinine clearance and the frequency of adverse renal events in African women without HIV during the 74 week postpartum period. More research is needed to support our findings. INTRODUCTION Tenofovir diphosphate fumarate (TDF) in combination with emtricitabine (FTC) has been widely used as pre‐exposure prophylaxis in adults at risk for Human Immunodeficiency Virus (HIV) when the Food and Drug Administration (FDA) first approved Truvada (TDF‐FTC) in 2012 [1] followed by the World Health Organization (WHO) recommendation in 2015 [2]. TDF‐FTC as pre‐exposure prophylaxis for pregnant and lactating women was only later recommended by the WHO in 2017 based on safety data generated from a handful of studies that included pregnant women who were exposed to TDF‐FTC as part of combination treatment for HIV or as prophylaxis for Hepatitis B [3, 4]. Additional evidence of the safety of TDF/FTC in pregnant women emerged from the programmatic implementation of the WHO recommendation. These observational and surveillance studies provided reassurance that TDF‐FTC did not contribute to adverse pregnancy outcomes [5, 6]. Subsequently, from a randomized controlled trial conducted between 2017 and 2020, we presented additional, robust evidence of no association between TDF‐FTC exposure and preterm births, stillbirths and low birth weight [7]. The toxicity of TDF use is underpinned by its excretion via glomerular filtration and proximal tubular secretion, which may, therefore, alter kidney function [8]. Tubular dysfunction may be associated with reduced phosphate reabsorption and phosphatemia, which in turn may affect bone mineralizsation. However, TDF is also hypothesized to directly affect bone tissue by altering gene expression in osteoclasts and osteoblasts, with resultant bone loss [9]. Whilst there is some evidence of compromised bone mineral density (BMD) in women living with HIV receiving TDF‐containing combination antiretroviral treatment [10, 11], studies of women not living with HIV and receiving TDF‐FTC as PrEP have demonstrated minimal or no changes in BMD in association with TDF‐FTC exposure [12, 13]. Furthermore, any minimal changes in BMD observed were reversed after discontinuation of TDF‐FTC PrEP [14]. Renal tubular dysfunction is characterized by proteinuria, glucosuria, phosphaturia and uricosuria and, as such, urine tests to determine the urine albumin‐to‐creatinine ratio, or a 24 h urine collection to calculate creatinine clearance and total protein excretion, are recommended sensitive tools for the early detection of kidney damage. These tests are costly and not practical for underresourced settings and should be reserved for individuals with chronic kidney disease (CKD) or with acute kidney injury (AKI). Nephrotoxicity associated with TDF in HIV prevention clinical trials involving healthy individuals is generally considered mild, as evidenced by small changes in serum creatinine levels and calculated creatinine clearance rates [15, 16]. These changes are often reversed when TDF is discontinued [17]. Data on the effect of TDF on renal function in pregnant and lactating women are limited. In a handful of studies of pregnant and lactating women living with HIV, reductions in CrCl during pregnancy and the postpartum period were more evident among women on TDF‐containing treatment than among those on non‐TDF‐containing regimens or not receiving ART. However, the authors interpreted these changes as not clinically significant [18, 19]. In the primary analysis of the CAP016 RCT, we reported no difference in renal function adverse events during pregnancy between TDF‐exposed and unexposed randomized arms [7]. In addition, as part of the postpartum safety monitoring in the CAP016 RCT, we provided further evidence that TDF‐FTC alone was not associated with changes in BMD and Bone Mineral Content (BMC) at the hip and lumbar spine of lactating women after adjusting for breastfeeding duration and body mass index [20], and in‐utero exposure to TDF‐FTC did not alter BMC in the infants [21]. In this analysis of postpartum safety data from the CAP016 RCT, we examined changes in creatinine clearance in lactating women at 6, 26, 54 and 74 weeks postpartum in women who were randomized to initiate TDF‐PrEP at enrolment in pregnancy (Immediate PrEP Arm) versus women who deferred initiation of TDF‐PrEP to the time of breastfeeding cessation (Deferred PrEP Arm). We also explored the dose–response relationship between TDF‐FTC and creatinine clearance. As a secondary objective, we examined the relationship between creatinine clearance and BMD at the hip and lumbar spine, given that renal function alone can also contribute to BMD changes, and our previously published report did not find an association between TDF‐FTC exposure and BMD changes in this study population [20]. MATERIALS AND METHODS Study design and setting The CAP016 study was an open‐label randomized controlled clinical trial designed to examine the safety of TDF‐FTC PrEP use during pregnancy and breastfeeding. The study was conducted at a hospital‐based research facility in KwaZulu Natal, South Africa. Safety data on pregnancy was published in 2024 with a detailed description of the study population and procedures [7]. Participants Pregnant women not living with HIV, 18 years or older, at substantial risk for HIV infection, with no serious illnesses, with creatinine clearance of >70 mL/min and <28 weeks of gestation were randomized to either initiating daily oral TDF‐FTC PrEP at enrolment (Immediate PrEP) or delayed TDF‐FTC PrEP until breastfeeding cessation (Deferred PrEP). Participants were followed up monthly during pregnancy and at 6, 26, 54 and 74 weeks post delivery. The CAP016 parent study was registered on ClinicalTrials.gov under NCT03227731. Randomization and masking Pregnant women meeting eligibility criteria and providing written informed consent were randomly assigned (1:1) to immediate initiation of PrEP in pregnancy (immediate PrEP group) or deferred initiation of PrEP at cessation of breastfeeding (deferred PrEP group). A computer‐generated permuted block (block size of 10) randomization list was generated by the study biostatistician and used to prepare sealed envelopes with sequential participant study numbers. In this open‐label non‐placebo clinical trial, study staff and participants only learned of the assigned treatment group (Immediate initiation of PrEP or Deferred initiation of PrEP to time of breastfeeding cessation) at the time of randomization. Procedures Participants included in this substudy were recruited between 28 September 2017 and 3 December 2019. Maternal data collected during pregnancy and/or postpartum included age, weight, height, duration on TDF‐FTC PrEP and duration of breastfeeding. Body mass index (BMI) was calculated (weight (kg)/ height2 (m2)) and graded according to WHO categories: Underweight (<18, 5 kg/m2), Normal (18, 5–24, 9 kg/m2), Overweight (25–29, 9 kg/m2), Obese (>30 kg/m2). Serum creatinine (μmol) was measured in real time by a commercial laboratory using the conventional Jaffe assay on the Beckman Coulter Analyzer at baseline in pregnancy and then at 6, 26, 54 and 74 weeks postpartum. Estimated creatinine clearance (mL/min) was calculated using the Cockroft–Gault equation, adjusted for female sex: [140‐age (years)] × [weight (kg) × 0.85/72 × Serum creatinine (mg/dL)]. Using the Division of AIDS Toxicity Grading Table [22], normal kidney function was defined by creatinine clearance greater than or equal to 90 mL/min, moderate kidney function as creatinine clearance between 60 and 90 mL/min (Grade 2) and abnormal kidney function if creatinine clearance was <60 mL/min (Grade 3). Women were evaluated at baseline during pregnancy, before randomization and at 6, 26, 54 and 74 weeks postpartum. For participants in the Immediate PrEP arm, intracellular tenofovir diphosphate (TFV‐DP) was quantified in dried blood spots (DBSs) collected at 26 and 54 weeks postpartum. Extractions from a 50‐μL DBS were tested for TFV‐DP using a validated high‐performance liquid chromatography–tandem mass spectrometry (LC–MS/MS) method at the University of Cape Town, South Africa. The lower limit for TFV‐DP quantification was 16.6 fmol/3‐mm punch. We extrapolated adherence thresholds based on TFV‐DP concentrations previously reported in a directly observed daily PrEP study among African pregnant women [23]. In a subset analysis, we estimated a dose–response relationship between creatinine clearance and change in creatinine clearance for the following TFV‐DP concentrations: <200 fmol/punch (equivalent to less than 2 doses/week), 200–400 fmol/punch (2–4 doses/week), 400–600 fmol/punch (4–6 doses/week) and >600 fmol/punch (7 doses/week). Participants had dual‐energy x‐ray absorptiometry (DXA) scans of the hip and lumbar spine performed by a trained radiographer at 6, 26, 54 and 74 weeks postpartum, and bone mineral density (g/cm2) at the lumbar spine and hip was documented at each visit. Outcomes The primary outcome variables of this secondary analysis were creatinine clearance and percent change in creatinine clearance as well as frequency of renal adverse events as defined by CrCl <90 mL/min between randomization arms. Exploratory outcomes include bone mineral density at the hip and lumbar spine. Statistical analysis Statistical analysis was performed using Stata 18.0 (StatCorp. 2023. Stata Statistical Software: Release 18. College Station, TX: StataCorp LLC). The Shapiro–Wilk test was used to assess the normality of the data distribution. Student t‐tests assuming unequal variances with two‐sided p values were used to compare mean baseline variables, as well as Creatinine clearance (CrCl) at weeks 6, 26, 54 and 74 weeks, and mean percentage change in CrCl from 6 to 74 weeks between randomization arms. Mixed effects linear regression models were used to test for longitudinal differences in mean CrCl and change in CrCl between randomization arms, whilst adjusting for age, body mass index and breastfeeding duration. Interactions between time and treatment group were tested and dropped from the models if p > 0.2. We used the Student t‐tests assuming unequal variances to compare bone mineral density and adverse renal events at each time point. For comparisons between Immediate PrEP and Deferred PrEP arms, t‐tests for numeric data and Chi‐square test or Fisher's exact test (small frequencies) for categorical data were used. We applied Wilcoxon/Kruskal–Wallis tests for continuous data and χ2/Fisher exact tests for categorical data, as appropriate. The frequency of adverse renal events between randomization arms was examined using χ2/Fisher exact tests to determine the odds ratio for factors potentially associated with adverse renal events. Ethical consideration The parent study (CAP016) was approved by the University of KwaZulu Natal Institutional Review Board (BFC 243/16) and was approved by the South African Regulatory Authority (SAHPRA) in October 2016. This substudy was approved by the University of KwaZulu‐Natal Biomedical Research Ethics Committee (BREC/00003767/2022). Participants signed a written informed consent that included study follow‐up procedures and sample storage. Laboratory specimens, evaluation forms, reports and other records were identified only by a study number to maintain participant confidentiality. Data access was limited to authorized personnel. RESULTS In the CAP016 study, 540 pregnant women without HIV were randomized to either initiate PrEP (n = 271) in pregnancy (Immediate PrEP arm ‐IP) or defer PrEP initiation (n = 269) to the time of breastfeeding cessation (Deferred PrEP arm ‐DP). At baseline, age, body mass index (BMI), serum creatinine and creatinine clearance were comparable between the IP and DP arms. The mean (SD) age of women in the DP and IP arms was 23.8 (4.8) and 24.1 (4.7) years, respectively (p = 0.496). Overall, 338 (62.6%) were <25 years, 188 (34.8%) were between 25 and 35 years and 14 (2.6%) were older than 35 years. The mean (SD) BMI of women in the DP and IP arms was 27.9 kg/m2 (7.5) and 28.3 kg/m2 (5.6), respectively (p = 0.584). Thirty‐four percent (34%) of pregnant women were classified as obese. Mean baseline serum creatinine was 42.4 μmol in the IP arm and 42.5 μmol in the DP arm (p = 0.879). Mean creatinine clearance (SD) was 204.3 (45.1) mL/min in the IP arm and 200.1 (47.7) mL/min in the DP arm (p = 0.294). Participants were recruited between 28 September 2017 and 3 December 2019. Of the 540 pregnant women randomized to the IP and DP arms, 385 (71.3%), 239 (44.3%), 141 (26.1%) and 165 (30.6%) women were evaluated post‐delivery at 6, 26, 54 and 74 weeks, respectively (Figure 1). Consort diagram for the CAP016 pregnancy and postpartum study participation (September 2017–November 2021). There were negligible differences between the mean creatinine clearance at each visit between DP and IP Arms (6 weeks p = 0.254, 26 weeks p = 0.732, 54 weeks p = 0.653 and 74 weeks p = 0.889) (Table 1). Creatinine clearance between 6 and 74 weeks increased on average by 4.96% in the IP arm and 5.63% in the DP arm mean difference −0.67% [95% CI: (−6.10% to 4.77%), p = 0.809] (Table 1). TABLE 1Mean difference in CrCl between randomization arms at 6, 26, 54 and 74 weeks post‐delivery and % change in CrCl between 6 and 74 weeks. N Deferred PrEP (DP) arm mean (SD) N Immediate PrEP (IP) arm mean (SD)Mean difference (95% CI) IP arm‐DP arm p‐valueCrCl at 6 weeks181141.34 (34.92)204145.42 (34.92)4.08 (−2.94 to 1.11)0.254CrCl at 26 weeks114146.15 (36.41)125144.48 (38.73)−1.67 (−11.24 to 7.91)0.732CrCl at 54 weeks70147.4 (35.20)71150.51 (46.05)3.11 (−10.54 to 16.75)0.653CrCl at 74 weeks81153.95 (41.41)84154.87 (43.28)0.92 (−12.10 to 13.94)0.889 % change in CrCl 6–74 weeks 775.63% (16.64%)824.96% (18.07%)−0.67% (−6.10% to 4.77%)0.809 Mean difference in CrCl between randomization arms at 6, 26, 54 and 74 weeks post‐delivery and % change in CrCl between 6 and 74 weeks. % change in CrCl 6–74 weeks Using a longitudinal mixed‐effects linear regression model, whilst both outcomes showed increases relative to 6 weeks, randomization arm (IP vs. DP) did not correlate with percentage change in creatinine clearance (β = −2.08; p = 0.094) after adjusting for other variables in the model (Table 2). Body Mass Index was positively associated with creatinine clearance (β = 5.36; p < 0.001), whilst age was negatively associated with creatinine clearance (β = −2.11; p < 0.001). TABLE 2Correlates of percent change in creatinine clearance postpartum over time using mixed effects linear regression models.Coefficient β (95% CI) p‐valueRandomization arm (IP vs. DP)−2.08 (−4.52 to 0.36)0.094Weeks post delivery26 vs. 62.36 (0.06 to 4.66)0.04454 vs. 62.73 (0.26 to 5.43)0.04874 vs. 65.61 (3.08 to 8.13)<0.001Body mass index0.53 (0.30 to 0.75)<0.001Duration of breastfeeding (weeks)−0.01 (−0.05 to 0.38)0.803Age (Years)−0.28 (−0.54 to −0.19)0.036Hip BMD−7.98 (−19.71 to 3.74)0.182Spine BMD−5.48 (−19.00 to 8.04)0.427 Correlates of percent change in creatinine clearance postpartum over time using mixed effects linear regression models. Figure 2 shows that the profiles of creatinine clearance over time in each randomization arm were parallel, indicating equivalent rates of change and no difference between arms in the adjusted model. Women in the IP arm received TDF‐FTC PrEP for a median duration of 38 (IQR 22–88) weeks, and the duration of TDF‐FTC exposure did not affect creatinine clearance (β = −0.199; p = 0.410). The mean (SD) TFV‐DP level among 192 women in the IP arm in the postpartum period was 269 (338) fmol/punch. TFV‐DP was not detected in 62 (32.3%) women throughout the postpartum period. Notably, none of the women in the DP arm chose to initiate TDF‐PrEP at the time of breastfeeding cessation or by the time of study exit at 74 weeks. To estimate adherence levels, we extrapolated from TFV‐DP levels to adherence (number of doses taken per week) in the postpartum period; 49 (25.5%) women took less than two doses per week, 22 (11.5%) took between 2 and 4 doses per week, 23 (12.0%) took 4–6 doses per week and 36 (18.8%) women took seven doses per week. In the subset analysis, after adjusting for age and BMI, there was no dose effect of TFV‐DP on the percentage change in creatinine clearance between 6 and 74 weeks (Table 3). Adjusted mean creatinine clearance (mL/min) in the immediate PrEP versus the deferred PrEP arms at 6, 26, 54 and 74 weeks post delivery. TABLE 3Effect of the TFV‐DP level on change in creatinine clearance over time in the immediate PrEP Arm (n = 161).Percentage change in creatinine clearance coefficient β p‐valueTime effect (weeks post delivery)26 weeks vs. 6 weeks−0.4040.76854 weeks vs. 6 weeks0.6330.69774 weeks vs. 6 weeks5.484<0.001TFV‐DP level (fmol/punch)201–400 (n = 22) vs. <200 (n = 49)−2.5150.307401–600 (n = 23) vs. <200 (n = 49)−1.0630.697>600 (n = 36) vs. <200 (n = 49)−3.2920.135Undetectable vs. <200−4.4880.024Missing data vs. <200−3.9650.216Body mass index0.3680.003Age−0.4150.013 Effect of the TFV‐DP level on change in creatinine clearance over time in the immediate PrEP Arm (n = 161). Pregnant women with a creatinine clearance rate <70 mL/min were excluded from enrolment in the CAP016 PrEP RCT. At baseline, 2/539 (0.4%) pregnant women had a CrCl rate between 70 and 90 mL/min, suggestive of moderate renal function, which reverted to normal renal function post‐delivery. Whilst there were no incident cases of abnormal renal function (CrCl <60 mL/min) throughout the 74‐week follow‐up period, we did observe a decline in renal function from >90 mL/min to < 90 mL/min among 9 women in the IP arm and 7 in the DP arm. Overall, there were 16 (4%) Grade 2 CrCl abnormalities are suggestive of moderate renal function in the total study population during the postpartum period, and the proportion of women with these renal adverse events did not differ between IP (9/209, 4.3%) and DP (7/193, 3.6%) arms (OR 1.2; 95% CI 0.4–3.3) (p = 0.802) (Table 4). Among the 16 women, these Grade 2 adverse events were first observed at 6 weeks among 10 women and at 26 weeks among 6 women. Being underweight (BMI <18.5 kg/m2) was associated with a moderate renal adverse event (CrCl <90 mL/min) (OR 71.8; 95% CI 17.0–302.8) (p < 0.0001). TABLE 4Determinants of renal adverse events (moderate creatinine clearance) in the postpartum period a . N Normal creatinine clearance (≥90 mL/min) N Moderate creatinine clearance (60 < 90 mL/min)Mean difference (95%) moderate vs. normal CrCl p‐valueMean (SD) bone mineral density at the hip (g/cm2)6‐weeks2740.94 (0.12)150.86 (0.11)−0.08 (−0.14 to −0.02)0.01026‐weeks2140.91 (0.13)130.81 (0.11)−0.10 (−0.17 to −0.03)0.00554‐weeks1940.92 (0.13)100.79 (0.09)−0.12 (−0.21 to −0.04)0.00374‐weeks2440.92 (0.12)130.82 (0.10)−0.10 (−0.17 to −0.04)0.006Mean (SD) bone mineral density at the lumbar spine (g/cm2)6‐weeks2730.98 (0.12)150.87 (0.07)−0.11 (−0.15 to −0.06)<0.00126‐weeks2160.96 (0.11)130.86 (0.07)−0.10 (−0.13 to −0.06)<0.00154‐weeks1940.98 (0.12)100.88 (0.05)−0.10 (−0.14 to −0.06)0.00474‐weeks2430.98 (0.13)130.90 (0.06)−0.08 (−0.12 to −0.04)0.004 a Participants in the Immediate PrEP arm only. Determinants of renal adverse events (moderate creatinine clearance) in the postpartum period a . Participants in the Immediate PrEP arm only. In comparing women with moderate renal function (CrCl <90 mL/min) and women with normal renal function (CrCl >90 mL/min), there were small but important differences in the mean bone mineral density at the hip and lumbar spine at 6, 26, 54 and 74 weeks in the postpartum period (Table 5). TABLE 5Bone mineral density at the hip and lumbar spine by clinical staging of renal function (pooled sample). N Normal creatinine clearance (≥90 mL/min) n (%)Moderate creatinine clearance (60 < 90 mL/min) n (%)Unadjusted odds ratio (95% CI) p‐valueRandomization armImmediate PrEP209200 (95.7%)9 (4.3%)Deferred PrEP193186 (96.4%)7 (3.6%)1.20 (0.44–3.28)0.802TFV‐DP (fmol/punch) a ≥4005554 (98.2%)1 (1.8%)<400126118 (93.7%)8 (6.4%)0.27 (0.03–2.24)0.280Age (years)>351111 (100%)0≤35391375 (95.9%)16 (4.1%)Undefined1.000Body mass index<18.5114 (36.4%)7 (63.6%)≥18.5294287 (97.6%)7 (2.4%)71.8 (17.01–302.60)<0.001 a Participants in the Immediate PrEP arm only. Bone mineral density at the hip and lumbar spine by clinical staging of renal function (pooled sample). Participants in the Immediate PrEP arm only. DISCUSSION Although TDF‐based PrEP is recommended for adults at substantial risk for HIV acquisition, pregnant and lactating women were excluded from PrEP efficacy trials, hence no robust evidence exists for the effect of TDF‐PrEP on renal function during pregnancy and lactation. The CAP016 RCT previously reported robust, reassuring safety data of TDF‐FTC PrEP use in pregnant women, which included renal adverse events during pregnancy across randomization arms [8]. In a longitudinal evaluation of safety data collected during the 74‐week postpartum period, creatinine clearance at 6, 26, 54 and 74 weeks and the change in creatinine clearance between 6 and 74 weeks did not differ between Immediate TDF‐FTC PrEP and Deferred TDF‐FTC PrEP arms. Whilst adjusting for BMI and age, both of which independently influenced creatinine clearance, our subset analysis also demonstrated that creatinine clearance was not altered by the presence of higher levels of TFV‐DP, suggestive of moderate to good adherence to the oral daily TDF‐FTC PrEP regimen. The number of renal adverse events was relatively small in the postpartum period, and the occurrence of these moderate adverse events did not differ between the IP and DP arms. We showed no evidence of an effect of TDF‐FTC on the rate of creatinine clearance in our postpartum population who were followed up for 18 months and exposed to TDF‐FTC PrEP for approximately 9 months since randomization in pregnancy. Other TDF‐PrEP efficacy studies have reported small and non‐clinically significant decreases in creatinine clearance in the first 12 weeks of use, and these changes tend to stabilize thereafter [16, 17]. We found that BMI positively correlated with creatinine clearance, a finding consistent with the study by Gerchman et al. [24], who reported higher BMI to be associated with greater creatinine clearance independent of body fat distribution. Whilst a higher BMI resulted in higher creatinine clearance, any deleterious effect of TDF‐exposure on creatinine clearance could have been masked by the high prevalence of obesity in our population. It must be noted that a third of our study population (33.7%) were classified as obese before randomization in pregnancy and remained obese by 6 months postpartum. Nonetheless, we did adjust for obesity in the regression analysis, and TDF‐FTC exposure remained unrelated to the rate of creatinine clearance. Consistent with other PrEP studies, we did identify a small number (<5%) of Grade 2 renal adverse events in the postpartum period, and the proportion of women with a moderate adverse event was not different between randomization arms. Notably, being underweight (BMI <18.5 kg/m2) was a statistically significant risk factor for a decline in renal function to moderate renal function (CrCl <90 mL/min) in the postpartum period. Like in other PrEP clinical trials, it is not surprising that the number of clinical adverse events in our study is few, irrespective of TDF‐exposure, since participants with pre‐existing renal abnormalities (CrCl <70 mL/min) are excluded [25, 26, 27]. Whilst age was negatively associated with creatinine clearance rate in our postpartum population, women >35 years did not experience any renal adverse event independent of TDF‐PrEP exposure. Being older than 40 years of age has been reported in other studies as a predictor of new‐onset renal disease [16, 25]; however, it must be noted that our study population predominantly comprised young pregnant women, with only 14 (2.6%) aged between 35 and 40 years. Our intent‐to‐treat analysis did not demonstrate a difference in the glomerular filtration rate (creatinine clearance) between the Immediate PrEP and Deferred PrEP arms whilst adjusting for BMI and age. Understandably, adherence to the daily oral TDF‐FTC regimen has been reported as suboptimal in most studies of pregnant and lactating women [28, 29]. In our study, TFV‐DP levels >400 fmol/punch were detected in only 30.7% of women in the IP arm by 6 months post delivery. This means that the vast majority (70%) of women took between 1 and 4 doses per week instead of the recommended seven doses per week. Our exploratory post hoc analysis suggests no association between creatinine clearance and exposure to higher levels of TFV‐DP after adjusting for BMI and age. However, our analysis was notably underpowered by the vast majority of women who were less adherent to the daily regimen, and any association between creatinine clearance and exposure to higher levels of TDF‐DP remains inconclusive. We have recently reported that TDF‐FTC PrEP use during pregnancy in the CAP 016 RCT had no direct effect on bone mineral density and bone mineral content at the hip and lumbar spine of African breastfeeding women after adjusting for BMI and breastfeeding [20]. Yet other PrEP studies demonstrated small but significant changes in BMD associated with TDF‐PrEP use without adjusting for creatinine clearance [30, 31, 32]. In this exploratory analysis, we further examined the potential effect of glomerular filtration on BMD at the hip and lumbar spine of postpartum women. We observed small t differences in BMD at the hip and spine between women with moderate glomerular filtration rates in comparison to women with normal glomerular filtration rates, thus confirming an independent association between the glomerular filtration rate and bone mineral density as seen in studies of older women with chronic renal disease [33] and suggesting that the glomerular filtration rate should be adjusted for when examining the effect of TDF‐PrEP on bone mineral density. Study strengths and limitations To our knowledge, this is the first randomized controlled study with a longitudinal evaluation of creatinine clearance in African women without HIV and either exposed to TDF‐FTC PrEP during pregnancy and postpartum or deferred TDF‐FTC PrEP until cessation of breastfeeding. In addition, we were able to assess a TFV‐DP dose‐effect on creatinine clearance, considering adherence to PrEP was suboptimal in 70% of the study population randomized to the Immediate PrEP arm. We acknowledge some important limitations in this study. Although we enrolled over 500 pregnant women, the study suffered a severe attrition in follow‐up post delivery due to the COVID‐19 pandemic. As a result, up to 52% of the study population who had enrolled in the CAP016 RCT had not returned after delivery or did not return for all visits, resulting in missing data. To account for the substantial amount of missing data in the postpartum period, Table S1 compares baseline characteristics and antenatal CrCl profiles between randomization arms, and Tables S2–S5 compare baseline characteristics and antenatal CrCl profiles between women lost to follow‐up and women included in the analysis at each postpartum follow‐up visit. Of note, baseline characteristics were comparable between women who were lost to follow‐up and women who remained in follow‐up. This was evident across randomization arms. Retention was significantly higher during pregnancy, and we demonstrated that antenatal CrCl profiles were similar across randomization arms. We further explored if these antenatal CrCl profiles were different between women lost in the postpartum period vs. women retained in the postpartum period. Whilst mean CrCl values during pregnancy were lower among women who were lost to follow‐up, the change in CrCl from baseline to the last antenatal visit was not different between these groups. Our supplementary data however suggest that the loss‐to‐follow‐up may not be entirely random, and women in the Deferred PrEP arm retained in the study at 74 weeks had higher CrCl rates in pregnancy than women who were lost to follow‐up. As a result, the better renal outcomes we report at later visits in both randomization arms may be biased by the high attrition rate. We did not explore other statistical methods, such as multiple imputations for missing data. The possibility that the data was missing not at random limits the usefulness of multiple imputation in this case. We also acknowledge that creatinine clearance is not the gold standard for assessing glomerular filtration and may have underestimated the true effect of TDF‐FTC PrEP on glomerular filtration. Furthermore, we did not assess the effect of TDF‐FTC PrEP on proximal tubule function, for which any abnormality is said to occur before changes to glomerular filtration. CONCLUSIONS The lack of evidence of an association between TDF‐based PrEP and glomerular filtration in our African population without HIV remains inconclusive, considering the high attrition rate in postpartum follow‐up. However, our valuable data may contribute to the ongoing surveillance of the safety of TDF‐PrEP in pregnant and lactating women. Whilst other studies have identified small but significant reductions in creatinine clearance and a higher number of renal adverse effects among adults exposed to TDF‐PrEP, these events appear to be more common among older individuals and those with a baseline creatinine clearance <90 mL/min. Our study findings suggest that being underweight (BMI <18.5 kg/m2) and having a baseline creatinine clearance <90 mL/min increases the likelihood of adverse renal events. We have demonstrated that underweight women are more likely to have moderate renal impairment, and further studies are recommended to establish if underweight women require more frequent monitoring of creatinine clearance when using TDF‐PrEP. Whilst screening for renal function abnormality is essential before initiating TDF‐PrEP, the availability of results should not deter initiation of PrEP since the vast majority of pregnant and lactating women without HIV are unlikely to have early signs of renal dysfunction. Furthermore, our study findings suggest that less frequent monitoring of creatinine clearance in the vast majority of pregnant and lactating women using TDF‐PrEP may be a more cost‐effective strategy to monitoring the safety of TDF‐PrEP in resource‐limited countries. In conclusion, tenofovir disoproxil fumarate, when given in combination with emtricitabine as pre‐exposure prophylaxis during pregnancy and lactation, appears not to have an effect on creatinine clearance in African women without HIV during the 74‐week postpartum period; however, this association remains inconclusive considering the high attrition rate. Whilst earlier studies have provided reassuring evidence of the safety of TDF‐FTC PrEP in pregnant and lactating populations, additional studies of large population groups, such as surveillance programs, are needed to establish a longitudinal safety profile of TDF/FTC ‐PrEP in pregnant and lactating women. AUTHOR CONTRIBUTIONS G.K. and D.M. conceptualized the study, sought financial support for the project, provided oversight of study conduct and formal analysis of study data and wrote the first draft of the manuscript. T.E. conducted the formal analysis of study data and contributed to writing the first draft. M.N. and A.C.D. played a key role in the conduct of the research and data collection. All authors reviewed, commented on and approved this manuscript before submission for publication. All authors had access to all the data in the study. FUNDING INFORMATION This study was supported by the South African Medical Research Council and Gilead Sciences, Inc. Investigational product was provided by Gilead Sciences, Inc. Supporting information Table S1. Comparison of baseline characteristics and CrCl (mL/min) during pregnancy between randomization arms. Table S2. Comparison of Baseline Characteristics and Antenatal CrCl (mL/min) of Women included in Analysis at 6 Weeks and Women Lost to Follow‐up Stratified by Randomization Arm (Students t‐test). Table S3. Comparison of Baseline Characteristics and Antenatal CrCl (mL/min) of Women included in Analysis at 26 Weeks and Women Lost to Follow‐up Stratified by Randomization Arm (Students t‐test). Table S4. Comparison of Baseline Characteristics and Antenatal CrCl (mL/min) of Women included in Analysis at 54 Weeks and Women Lost to Follow‐up Stratified by Randomization Arm (Students t‐test). Table S5. Baseline Characteristics of Women included in Analysis at 74 Weeks and Women Lost to Follow‐up Stratified by Randomization Arm (Students t‐test).